Hotel reservation/booking
Our partner Graz Tourism will be happy to assist you with your hotel booking.
contact Ms. Lisa Legat
+43/316/8075-66
lisa.legat@graztourismus.at
guided city tours:
August 31st, 19:00, meeting point: Graz Main Square, City Hall
September 2nd, 20:00, meeting point: Graz Main Square, City Hall
Venue
The 19th ESBRA Congress takes place at the Medical University of Graz in Austria. For non-European arrivals, we recommend arriving by plane at the airport “Graz”. Alternatively, you can fly to the airport “Vienna-Schwechat” and take the train to “Graz Central Station” afterwards. To get to the congress venue, the Medical University of Graz, please take tram line 7 and get off at the terminus “MedUni/Klinikum Nord”.
Venue address: Neue Stiftingtalstraße 6, 8010 Graz
Organization Commitee
Dr. Daniel König-Castillo, Allgemeines Krankenhaus der Stadt Wien
Univ.-Prof. Dr. Carolin Lackner, Medizinische Universität Graz
Prof. Mickael Naassila, PhD, Université de Picardie Jules Verne
Univ.-Prof. Dr. Otto Lesch, Medizinische Universität Wien
Dr. Francesca Sarocchi, Medizinische Universität Graz
Dr. Verena Stangl, Medizinische Universität Graz
Univ.-Prof. Dr. Rudolf Stauber, Medizinische Universität Graz
Dr. Stephan Sygulla, Medizinische Universität Graz
Assoz. Prof. Priv.-Doz. Dr. Martin Wagner, Medizinische Universität Graz
Priv.-Doz. Dr. Jolana Wagner-Skacel, Medizinische Universität Graz
Program
8:00-9:00 Registration
AULA
9:00-9:30
Opening Ceremony
9:30-10:15
Plenary session 1: Epidemiology of alcohol-related organ disease in Europe
Chairs: R. Stauber; C. Lackner, Graz, AUT
Helena Cortez-Pinto, Lissbon, PRT
10:15-10:30 COFFEE BREAK AND POSTER VIEWING, Lecture Hall 5
TOPIC Alcohol-related burden of disease: epidemiologic, economic and social implications (1)
10:30-11:50
Session 1: Stigma in people with alcohol use disorder (AUD) or alcohol-related liver disease (ARLD)
Chairs: A. Dhanda, Plymouth, UK; P. Carrieri, INSERM, Marseille, FRA
10:30-10:50
What’s in a name? Can novel liver disease nomenclature reduce alcohol-related stigma and harms?
P. Mathurin, Lille, France
10:50-11:10
How to reduce stigma: a clinical and policy perspective
P. Carrieri, INSERM, Marseille, FRA
11:10-11:30
What can a hepatologist do to tackle stigma?
A. Dhanda, Plymouth, UK
11:30-11:50
Perspectives on stigma from people with lived experience of AUD and ARLD
L. Manning, UK
11:50-12:10 COFFEE BREAK AND POSTER VIEWING, Lecture Hall 5
TOPIC Alcohol-related burden of disease: epidemiologic, economic and social implications (2)
12:10-13:30
Session 2: New insights regarding individual and environmental factors associated with changes in alcohol use: population-based epidemiologic approaches
Chairs G. Airagnes, Paris, FRA
12:10-12:30
Bilateral relationships between cannabis and alcohol go mainly from cannabis to alcohol
J. Matta, Paris, FRA
12:30-12:50
Factors associated with self-reported changes in alcohol use among young adults during the COVID-19 pandemic: a comparative analysis between Canada and France
P.-J. Coulaud, Vancouver, CAN
12:50-13:10
Changes in alcohol use during the COVID-19 pandemic in health-students: The roles of other substance use and literacy in health
G. Airagnes, Paris, FRA
13:10-13:30
Atypical working hours and changes in alcohol use among workers from various sociodemographic backgrounds
N. Hamieh, Paris, FRA
13:30-14:30 LUNCH
ESBRA ECI Committee meeting, Institute of Pathology, Library
EBSRA Board meeting, Institute of Pathology, Meeting Room
TOPIC Social cognition and problematic alcohol use
14:30-15:50
Session 3: Recent advances in the study of social cognition and problematic alcohol use
Chairs: A. Pabst; P. Maurage, Louvain, BEL
14:30-14:50
Acute effects of alcohol on empathy in heavy drinking young adults
L. Kumar, Pittsburgh, USA
14:50-15:10
Longitudinal relationships between empathy and alcohol-related outcomes in heavy drinkers
E. Claus, The Mind Research Network, USA
15:10-15:30
Alcohol use disorder displays trait-related reductions in prosocial decision making
S. Jangard, Stockholm, SWE
15:30-15:50
Altered attention to facial features in patients with severe alcohol use disorder
A. Pabst, Louvain, BEL
15:50-16:10 COFFEE BREAK AND POSTER VIEWING, Lecture Hall 5
TOPIC Effects of binge-drinking in adolescence
16:10-17:30
Session 4: Binge drinking during adolescence: Latest developments
Chairs: P. Maurage, Louvain, BEL; L. Hipolito, Valencia, ESP
16:10-16:30
Stress, cognition, and alcohol use during adolescence: does acute stress play a role in cognitive impairments associated with risky alcohol consumption?
S. Suarez, Louvain, BEL
16:30-16:50
Microbiome and cognitive alterations in young binge drinkers
C. Carbia, Cork, IRL & Louvain, BEL
16:50-17:10
Alcohol-specific memory inhibition training in binge drinkers: a double-blind randomized controlled trial examining alcohol use and craving levels
N. Almeida-Antunes , Minho, PRT
17:10-17:30
Neurofunctional precursors to binge drinking in adolescents: longitudinal findings on electrophysiological functional connectivity profiles and executive control abilities
LF Antón Toro, Madrid, BEL
17:30-17:50 COFFEE BREAK AND POSTER VIEWING, Lecture Hall 5
TOPIC Genetic implications in alcohol-related organ damage
17:50-19:10
Session 5: Genetics of alcohol-related liver disease: risk factors, risk prediction and potential therapeutic approaches
Chairs: D. Seth, Sydney, AUS; M. Morgan, London, UK
17:50-18:10
Genetic and environmental risk factors for AUD and ALD
M. Morgan, London, UK
18:10-18:30
Genetic and lipid biology in liver disease
D. Seth, Sydney, AUS
18:30-18:50
Polygenic risk scores for risk stratification in ALD (virtual)
L. Schwantes-An, Indiana, USA
18:50-19:10
Hot topics and emerging themes: round up
D. Seth, Sydney, AUS; M. Morgan, London, UK
Hörsaal 3 (Lecture Hall 3)
TOPIC Alcohol-related liver injury: role of dysregulated lipid metabolism
10:30-11:50
Session 6: New insights into mechanisms of deysregulated lipid metabolism and its role in the progression of alcohol-associated liver disease
Chairs: C. Casey, Omaha, USA; M. McNiven, Rochester, USA
10:30-10:50
An ethanol-based disruption of the ubiquitin-proteasome transporter protein VCP induces hepatocyte steatosis by an accumulation of the LD-surface enzyme HSD17B13
M. McNiven, Rochester, USA
10:50-11:10
Role of long noncoding RNA H19 in regulation of lipid metabolism in alcohol associated liver disease
L. Gobejishvili, Louisville, USA
11:10-11:30
Host-derived 5S rRNA pseudogene transcripts are associated with inflammatory responses in alcohol-associated hepatitis
L. Nagy, Cleveland, USA
11:30-11:50
Is hepatic steatosis really a mandatory disease stage or just a bystander in alcohol-related liver disease?
S. Mueller, Heidelberg, GER
11:50-12:10 COFFEE BREAK AND POSTER VIEWING, Lecture Hall 5
TOPIC Gut-Liver-Axis (1)
12:10-13:30
Session 7: Gut-liver interaction in alcohol-associated organ damage
Chairs: K. Kharbanda, Omaha, USA; C. Casey, Omaha, USA
12:10-12:30
Ethanol-induced alterations in the gut-liver axis promotes alcohol-associated liver disease: Protection by betaine treatment
K. Kharbanda, Omaha, USA
12:30-12:50
Gut barrier impairment is key disease driver in ALD
S. Chokshi, London, UK
12:50-13:10
Calcium channels in the intestinal epithelium play a crucial role in alcohol-induced tissue injury at the gut-liver and gut-brain axis
R. Rao, Knoxville, USA
13:10-13:30
Role of microbiota dysbiosis and leaky gut in alcohol-induced organ damage
A. Keshavarzian, Chicago, USA
13:30-14:30 LUNCH
ESBRA ECI committee meeting (Pathology Library)
EBRA Board meeting (Pathology Meeting Room)
TOPIC Gut-Liver Axis (2)
14:30-15:50
Session 8: Role of intestinal microbiota, barrier dysfunction and autophagy for onset, progression and treatment of ALD
Chairs: I. Bergheim, Vienna, AUT; K. Ikejima, Tokyo, JPN
14:30-14:50
Gut-liver axis in ALD development: more than just the microbiome and dysbiosis
P. Stärkel, Saint-Luc, BEL
14:50-15:10
Modulation of the intestinal no homeostasis as trigger of intestinal barrier dysfunction in the development of alcohol-related disease
A. Baumann, Vienna, AUT
15:10-15:30
Pharmaco-nutritional approaches to metabolic dysfunction-associated fatty liver disease
A. Uchiyama, Tokyo, JPN
15:30-15:50
The role of autophagy and nuclear proteins in the pathophysiology of steatohepatitis
S. Yamashina, Tokyo, JPN
15:50-16:10 COFFEE BREAK AND POSTER VIEWING, Lecture Hall 5
TOPIC Gut-Liver-Brain Axis (1)
16:10-17:50
Session 9: Metabolomics as a new tool to investigate the gut-liver-brain axis and the treatment response in AUD
Chairs: P. de Timary; C. Carbia, Louvain, BEL
16:10-16:30
Untargeted and target lipidomics reveal sphingomyelins as a driver of small gut T-cell apoptosis in alcohol use disorder (AUD) patients
P. Stärkel, Louvain, BEL
16:30-16:50
Comparison of metabolite profiles of persons with progressive ALD to persons with non-progressive ALD and healthy controls identify possible metabolic processes associated with progressive ALD
E. Puhakka, Kuopio/Joensuu, FIN
16:50-17:10
Gut microbiota-derived metabolites and their potential neuroactive properties, as a way to investigate the gut-brain axis in AUD patients
S. Leclercq, Louvain, BEL
17:10-17:30
Baseline metabolite profile could be useful for personalized medicine in AUD patients
O. Kärkkäinen, Kuopio/Joensuu, FIN
17:30-17:50 COFFEE BREAK AND POSTER VIEWING, Lecture Hall 5
TOPIC Mechanisms of cholestasis in alcohol-related liver disease
17:50-18:30
Session 10: Key note lecture 1. Mechanisms of cholestasis in alcohol-related liver disease
Chairs: R. Stauber, Graz, AUT; H. Denk, Graz, AUT
P. Fickert, Graz, AUT
Hörsaal 4 (Lecture Hall 4)
TOPIC Management of alcohol-use disorder (1)
10:30-11:50
Session 11: Treatment of alcohol use disorder: safety and efficacy of precision medicine in selected patients
Chairs: J. Chick, Castle Craig, UK; G. Addolorato, Rome, IT
10:30-10:50
Why we need new anti-craving medications
H. Alho, Helsinki, FIN
10:50-11:10
Subgroups of alcohol dependence and their special treatment
O. Lesch, Vienna, AUT
11:10-11:30
New approaches in the treatment of alcohol dependence (virtual)
B. Johnson, Miami, USA
11:30-11:50
Treatment of AUD in patients with different severity of liver disease
G. Addolorato, Rome, IT
11:50-12:10 COFFEE BREAK AND POSTER VIEWING, Lecture Hall 5
TOPIC Management of alcohol-use disorder (2)
12:10-13:30
Session 12: How to improve cognitive abilities to favor treatment outcome? New perspective and innovative tools
Chairs: AL. Pitel, Caen, FRA; P.Maurage, Louvain, BEL
12:10-12:30
Cognitive training and remediation for substance use disorders
A. Verdejo-Garcia, Monash, AUS
12:30-12:50
Mindfulness-based relapse prevention for drinking reductions
K. Witkiewitz, Albuquerque, USA
12:50-13:10
Preventing relapse in alcohol disorder using sensori-motor EEG-neurofeedback training: an event-related potentials study
C. Dousset, Brussels, BEL
13:10-13:30
The use of Virtual reality and 360° immersive videos to study and treat alcohol abuse and addiction
E. Quertemont, Liege, BEL
13:30-14:30 LUNCH
ESBRA ECI committee meeting (Pathology Library)
EBRA Board meeting (Pathology Meeting Room)
TOPIC Management of alcohol-use disorder (3)
14:30-15:50
Session 13: Sodium oxybate for the treatment of alcohol dependence: results from an international clinical development and research project and perspectives
Chairs: O. Lesch, Vienna, AUT; W. van den Brink, Amsterdam, NL
14:30-14:50
Sodium oxybate for the treatment of alcohol use disorder: well-tolerated over 30+ years of clinical use
H. Walter, Vienna, AUT
14:50-15:10
Sodium oxybate for the treatment of alcohol withdrawal syndrome: results from two Phase 3 randomized, double-blind, active-controlled trials
O. Lesch, Vienna, Austria
15:10-15:30
Sodium oxybate for the maintenance of abstinence in alcohol dependent patients: results from a Phase 3 international, multicenter, randomized, double-blind, placebo-controlled trial
W. van den Brink, Amsterdam, NL
15:30-15:50
The effect of population severity and treatment duration on sodium oxybate efficacy in the maintenance of abstinence in alcohol dependent patient
J. Guiraud, Amsterdam, NL
15:50-16:10 COFFEE BREAK AND POSTER VIEWING, Lecture Hall 5
TOPIC The role of the nucleus of the amygdala (CeA) for regulation of behavioural dysfunctions related to alcohol exposure
16:10-17:30
Session 14: Central nucleus of the amygdala and alcohol use disorder: Perspectives from studies in mice to humans
Chairs: M. Roberto, La Jolla, USA; K. Radwanska, Warsaw, POL
16:10-16:30
Innate immune-related mechanisms in AUD: a view from the tipsy amygdala synapses
M. Roberto, La Jolla, USA
16:30-16:50
A central amygdala molecular mechanism in punishment-resistant alcohol self-administration
E. Domi, Linköping, SWE and Camerino, IT
16:50-17:10
Role of the epigentic enzyme EZH2 in compulsive alcohol intake
E. Barbier, Linköping , SWE
17:10-17:30
Arc controls alcohol relapse by a central amygdala mechanism
K. Radwanska, Warsaw, POL
17:30-17:50 COFFEE BREAK AND POSTER VIEWING, Lecture Hall 5
TOPIC Young Investigators at the Medical University of Graz
17:50-19:10
Session 15: The role of fibroblast growth factor (FGF 19) in alcohol-related organ disease
Chairs: J. Wagner-Skacel; M. Wagner, Graz, AUT
17:50-18:10
FGF21 and personality functioning: A potential marker of abstinence
J. Wagner-Skacel, Graz, Austria
18:10-18:30
Neuropeptid Y and FGF21 in the gut-liver-brain axis
A. Farzi, Graz, AUT
18:30-18:50
FGF21 supresses alcohol consumption through an amygdalo-striatal circuit
A. Horvath, Graz, AUT
19:20-23:00 Social program: Bus transfer to the barbecue evening at the mountain hut “Latschen-Hütte”, Teichalm
AULA
8:00 – 8:45
Plenary Session 2: Mallory-Denk bodies and hepatocellular ballooning. Historical perspectives, causes and consequences of protein misfolding in steatohepatitis
Chairs: C. Lackner, Graz, AUT
H. Denk, Graz, AUT
8:50 – 9:40
HELMUT SEITZ AWARD Lecture and Ceremony: Positive allosteric modulators of the GABAB receptor: A new class of ligands with therapeutic potential for alcohol use disorder
Chair: M. Naassila, Amiens, FRA
G. Colombo, Monserrato (CA), IT
9:45-10:00 COFFEE BREAK AND POSTER VIEWING, Lecture Hall 5
TOPIC Alcohol and carcinogenesis
10:00-11:20
Session 16: New paradigms in alcohol-associated carcinogenesis and tumor progression
Chair: A. Petrosyan, Omaha, USA; TBA
10:00-10:20
P53-destabilizing protein recruits NOTCH to mitochondria to reprogram liver tumor-initiating stem-like cells induced by alcohol
K. Machida, Los Angeles, USA
10:20-10:40
Adolescent- and adult-initiated alcohol exposure in mice differentially promote tumorigenesis and metastasis of breast Cancer
J. Luo, Iowa City, USA
10:40-11:00
The role of alcohol-induced Golgi disorganization and ER stress in the metastatic potential of prostate tumor
A. Petrosyan, Omaha, USA
11:00-11:20
Mechanisms of chronic alcohol exposure induced aggressiveness in cellular model of HCC and recovery after alcohol withdrawal
A. Courtois, Amiens, FRA
11:20-11:40 COFFEE BREAK AND POSTER VIEWING, Lecture Hall 5
TOPIC Alcohol-related multisystemic organ injury
11:40-13:00
Session 17: The multisystemic impact of unhealthy alcohol use; immune, metabolic, and neuropathological consequences
Chairs: P. Molina, New Orleans, USA;
11:40-12:00
Alcohol promotes Alzheimer’s disease progression through neuroinflammation and metabolic dysfunction
L. Coleman, Chapel Hill, USA
12:00-12:20
Contribution of alcohol associated metabolic instability to aging comorbidities
P.E. Molina, New Orleans, USA
12:20-12:40
Alcohol impact on gut-brain axis in Parkinson
A. Keshavarzian, Chicago, USA
12:40-13:00
Alcohol-induced suppression of hepatocyte innate immunity; disrupts parenchymal and non-parenchymal cell crosstalk and exacerbates viral pathogenesis
N. Osna, Omaha, USA
13:00-14:00
LUNCH
ESBRA Early-Career Investigators Committee: launch of mentorship program, Institute of Pathology, Library
TOPIC Young investigators at the Medical University of Vienna
14:00-15:30
Session 18: Early career investigators symposium
Chairs: D. König-Castillo; A. Kaltenböck, Vienna, AUT
14:00-14:20
Hepatic recompensation according to Baveno VII criteria is linked to a significant survival benefit in decompensated alcohol-related cirrhosis
B. S. Hofer, Vienna, AUT
14:20-14:40
Hepatic pIgR-mediated secretion of IgA limits bacterial translocation and prevents ethanol-induced liver disease in mice
D. Rajcic, Vienna, AUT
14:40-15:10
Sex disparities in outcome of patients with alcohol-related liver cirrhosis within the Eurotransplant network – A competing risk analysis
S. Weber, Vienna, AUT
15:10-15:30
Dissociative symptoms of patients with alcohol use disorder undergoing a qualitative study
S. Steirer, Vienna, AUT
15:30-15:50 COFFEE BREAK AND POSTER VIEWING, Lecture Hall 5
TOPIC Alcohol-induced progression to end-stage liver disease
15:50-17:10
Session 19: Alcohol-induced progression to end-stage liver disease
Chairs: N. Osna; K. Kharbanda, Omaha, USA
15:50-16:10
Novel translational aspects of hepatic iron accumulation in heavy drinkers
S. Müller, Heidelberg, GER
16:10-16:30
The role of H3K4 methylation in alcohol-associated liver disease resolution
I. Tikhanovich, Kansas, USA
16:30-16:50
Pro-fibrotic activation of hepatic stellate cells by engulfment of hepatocyte-derived apoptotic bodies generated in the context of HIV infection in response to ethanol metabolites
N. Osna, Omaha, USA
16:50-17:10
Overview on clinically relevant ex-vivo models of ALD including precision-cut liver slices and liver organoids
S. Chokshi, London, UK
17:10-17:30 COFFEE BREAK AND POSTER VIEWING, Lecture Hall 5
TOPIC Alcohol and bone injury
17:30-17:50
Session 20: Key-note lecture 3: Overview on compartment and cell-specific alcohol effects on bone involving oxidative-stress dependent and independent mechanisms and acetate
Chairs: M. Naassila, Amiens, FRA; S. Chokshi, London, UK
M. Ronis, New Orleans, USA
17:50-18:50
Session 21: Awardees of ESBRA travel fellowship: Presentation of graphical abstract
Chair: E. Palma, London, UK; ECIC Chair
18:10-18:30
Awardees 1-4
18:30-18:50
Awardees 5-8
Hörsaal 3 (Lecture Hall 3)
TOPIC Histology of alcohol-related liver disease
10:00-10:40
Session 22: Histological features of alcohol-related liver disease and implications for clinical management
Chairs: D. Tiniakos, Athens, GRC; C. Lackner, Graz, AUT
10:00-10:20
Histological features of alcohol-related liver disease and grading and staging
S. Sakellariou, GRC
10:20-10:40
High Resolution and single-fiber Digital Pathology and AI, from Liver Organoids to HCC and outcomes
M. Petitjean, PHARMANEST INC, Princeton, USA
10:40-11:20
Key note lecture 2: Digital assisted image analysis – emerging morphologic methods of tissue analysis. Potential impact and pitfalls
Chairs: H. Denk; K. Zatloukal, Graz, AUT
D. Tiniakos, Athens, GRC
11:20-11:40 COFFEE BREAK AND POSTER VIEWING, Lecture Hall 5
TOPIC Noninvasive assessment of liver fibrosis in alcohol related liver disease
11:40-13:00
Session 23: Noninvasive assessment of liver fibrosis in alcohol related liver disease
Chairs: I. Sporea, Timisoara, RO; S. Müller, Heidelberg, GER
11:40-12:00
Biological tests in ALD assessment
A. Popescu, Timisoara, RO
12:00-12:20
The place of elastography in ALD
I. Sporea, Timisoara, RO
12:20-12:40
How can we screen the ALD patients for liver fibrosis?
S. Müller, Heidelberg, GER
12:40-13:00
Non-invasive assessment of portal hypertension in patients with ALD
I. Grgurevic, Zagreb, HRV
13:00-14:00 LUNCH
TOPIC Management of alcohol-related liver disease: The patients perspective
14:00-15:30
Session 24: Patient centered management of compensated alcohol-related liver disease: Current status and unmet needs
Chairs: H. Stefanescu, Cluj-Napoca, RO
14:00-14:20
What does a patient with ARLD expect from the healthcare system?
ELPA representative / recording of H. Stefanescu interviewing a patient
14:20-14:40
Individual and societal determinants of ARLD screening (virtual)
M. Ventura Cots, Barcelona, ESP
14:40-15:10
Secondary prevention of ARLD in the Baveno VII era (virtual)
B. Procopet, Cluj-Napoca, RO
15:10-15:30
Integrated outpatient care systems for ARLD patients (virtual)
R. Fennel, Hull, UK
15:30-15:50 COFFEE BREAK AND POSTER VIEWING, Lecture Hall 5
TOPIC Management of alcohol-related liver disease (1)
15:50-17:10
Session 25: Management of alcohol-related liver disease – overview
Chairs: S.G. Rodrigues, Bern, CH; C. Becchetti, Milano, IT
15:50-16:10
Optimizing the management of alcohol use disorder in patients with liver disease (virtual)
P. Pfeifer, Bern, CH
16:10-16:30
How to best identify and stage liver fibrosis and risk of liver-related events? (virtual)
M. Thiele, Odense, DK
16:30-16:50
Advanced alcohol-related liver disease – managing the failing liver
S G. Rodrigues, Bern, CH
16:50-17:10
Liver transplantation in the ArLD: challenging old paradigms and shedding light on novel aspects
C. Becchetti, Milano, IT
17:10-17:30 COFFEE BREAK AND POSTER VIEWING, Lecture Hall 5
TOPIC Management of alcohol-related liver disease (2)
17:30-18:50
Session 26: Alcohol-related liver disease: what is new?
Chairs: C. Moreno, Brussels, BEL; C. Lackner, Graz, AUT
17:30-17:50
Strategies to identify in clinical practice alcohol-related liver disease patients before decompensated stage
E. Pose, Barcelona, ESP
17:50-18:10
How to define and manage patients with alcohol- related liver disease and metabolic syndrome?
A. Louvet, Lille, FRA
18:10-18:30
When to perform a liver biopsy in patients with alcohol-related liver disease?
R. Stauber, Graz, AUT
18:30-18:50
Severe alcohol-associated hepatitis: current management and future pipeline
P. Mathurin, Lille, FRA
Hörsaal 4 (Lecture Hall 4)
TOPIC Joint ESBRA-JMSAAS meeting
10:00-11:20
Session 27: Alcohol-related diseases: From brain to liver function
Chairs: S. Müller, Heidelberg, GER; K. Ikejima, JPN
10:00-10:20
Survey of the relationship between alcohol -related cognitive dysfunction and cerebral blood flow
T. Shirasaka, Sapporo, JPN
10:20-10:40
International cooperation in treatment of substance use disorders: The INTREPRET study in the Philippines
T. Harada, Tsukuba, JPN
10:40-11:00
Alcohol-related immune modulation during acute-on-chronic liver failure is associated with disease severity and progression
A. Riva, London, UK
11:00-11:20
Targeted reprogramming of inflammatory macrophages using prednisolone-loaded nanoliposomes attenuates alcohol-associated liver diseases
R. Bansal, Twente, Enschede, NL
11:20-11:40 COFFEE BREAK AND POSTER VIEWING, Lecture Hall 5
TOPIC Free oral presentations
11:40-13:10
Session 28: Free oral presentation (1)
Chairs: J. Wagner-Skacel, Graz, AUT; K. Zatloukal, Graz, AUT
11:40-11:50
Cannabidiol (CBD) to reduce alcohol consumption: a qualitative approach
C. Casanova, Marseille, FRA
11:50-12:00
The CNI model of moral decision making in severe alcohol use disorder
M. Gautier, Louvain-la-Neuve, BEL
12:00-12:10
Physiological manifestations of craving in binge-drinking and severe alcohol use disorder: a phenomenological approach
P. Billaux, Louvain-la-Neuve, BEL
12:10-12:20
The effects of N-acetylcysteine on intrinsic connectivity and neural alcohol cue reactivity in individuals with alcohol use disorder
W. Logge, Camperdown, AUS
12:20-12:30
A new statistical model for binge drinking pattern calssification in college students populations
J. Andre, Amiens, FRA
12:30-12:40
The Role of interoception in addictive disorders: A systematic review and a new framework
O. Desmedt, Lausanne, CH
12:40-12:50
Comparisons of structural brain alterations in patients with alcohol and cocaine use disorders
A. Maillard, Paris, FRA
12:50-13:00
Effects of proximal, contextual, and social alcohol cues on craving in an immersive virtual environment
M. Heck, Liege, BEL
13:00-13:10
A prospective comparison of bipolar I and II subjects with and without comorbid alcohol dependencefFrom the COGA dataset
U. Preuss, Ludwigsburg, GER
13:10-13:20
Psychedelics in AUD: From mechanisms to targeted intervention
M. Meinhardt, Mannheim, GER
13:00-14:00 LUNCH
TOPIC Gut-Liver-Brain Axis (2)
14:00-15:30
Session 29: Brain dysfunction in Alcohol-Related liver disease
Chairs: S. Chokshi; A. Hadjihambi, London, UK
14:00-14:20
No safe level of alcohol consumption for brain health
A. Topiwala, London, UK
14:20-14:40
Abnormal oxygen homeostasis as a major driver of alcohol and liver disease induced brain dysfunction
A. Hadjihambi, London, UK
14:40-15:10
Hepatic Encephalopathy: is it truly reversible following liver transplantation?
N. Weiss, London UK
15:10-15:30
Circulating novel biomarkers of neuronal injury have potential for the stratification and risk profiling of hepatic encephalopathy in cirrhosis
V. Patel, London, UK
15:30-15:50 COFFEE BREAK AND POSTER VIEWING, Lecture Hall 5
TOPIC Albumin & ALD
15:50-17:10
Session 30. Role of albumin in alcohol-related liver disease
Chairs: P. Caraceni Bologna, IT; R. Stauber, Graz, AUT
15:50-16:10
Structural and functional properties of human serum albumin
K. Oettl, Graz, AUT
16:10-16:30
The concept of effective albumin concentration in chronic liver failure
P. Caraceni, Bologna, IT
16:30-16:50
Molecular adsorbents recirculating system (MARS) in severe alcohol-related hepatitis
M. Kukla, Cracow, POL
16:50-17:10
Hepalbin-based extracorporeal liver support: first results
J. Stange, Rostock, GER
17:10-17:30 COFFEE BREAK AND POSTER VIEWING, Lecture Hall 5
TOPIC Iron and alcohol-related liver disease
17:30-18:50
Session 31. Iron overload in Alcohol Use Disorder – novel insights
Chairs: D.König-Castillo, Vienna, AUT; S. Hametner, Vienna, AUT
17:30-17:50
Enhanced red blood cell turnover is associated with alcoholic liver diseases and mortality
S. Müller, Heidelberg, GER
17:50-18:10
Hepatocyte efferocytosis of red blood cells: A novel mechanisms of liver iron overload in alcoholic liver disease
C. Zheng, Heidelberg, GER
18:10-18:30
Neurodegeneration associated with iron accumulation in the human brain
S. Hametner, Vienna, AUT
18:30-18:50
Brain iron overload and thiamine deficiency – a key pathway to explain and prevent cognitive decline in alcohol use disorder?
S. Listabarth, Vienna, AUT
AULA
8:00-8:45
Plenary session 3: A novel treatment strategy for alcohol use disorder with Phosphodiesterase 7 (PDE7) inhibitors
Chair: M. Naassila, Amiens, FRA
R. Ciccocioppo, Camerino, IT; Seattle, USA
8:50-9:45
NORDMAN Award Lecture & Award ceremony
Chair: M. Wojnar, Krakov, POL
S. Leclercq, Louvain, BEL
9:45-10:00 COFFEE BREAK AND POSTER VIEWING, Lecture Hall 5
10:00-10:40
GENERAL ASSEMBLY
TOPIC Alcohol-related inflammation and the brain
10:40-12:00
Session 32: Contribution of inflammatory mechanisms to alcohol-related brain abnormalities: a translational approach
Chairs: P. De Timary, Louvain, BEL; A. Pitel, Caen, FRA
10:40-11:00
Exploring the role of x-binding protein-1 (XBP1) in the gut-brain axis during alcohol-related liver disease
C. Sanz-García, Madrid, ESP
11:00-11:20
Investigating the evolution and the links between systemic inflammation, behavioral symptoms and brain structure during early alcohol cessation in alcohol use disorders
G. Petit, Louvain, BEL
11:20-11:40
Progression of microstructural alterations in the brain during early alcohol abstinence: neurobiological substrates, inflammation and therapeutic targets
M. Selim, Alicante, ESP
11:40-12:00
Different inflammatory pathways in severe alcohol use disorder
L. Lebedel, Caen, FRA
12:00-12:20 COFFEE BREAK AND POSTER VIEWING, Lecture Hall 5
TOPIC GABAB Receptor and alcohol use disorder
12:20-13:40
Session 33: GABAB Receptor and Alcohol Use Disorder: Preclinical and Clinical Update
Chairs: R. Agabio, Cagliari, IT; M. Naassila, Amiens, FRA
12:20-12:40
Sex-related difference in the efficacy of baclofen enantiomers on ethanol self-administration and dopamine transmission in rats
J. Jeanblanc, Amiens, FRA
12:40-13:00
Suppressing effects of KK-92A, a novel positive allosteric modulator of the GABAB receptor, on alcohol drinking and self-administration in alcohol-preferring rats
G. Colombo, Cagliari, IT
13:00-13:20
Baclofen and alcohol use disorder: Results from the latest Cochrane meta-analysis
R. Agabio, Cagliari, IT
13:20-13:40
Baclofen in alcohol use disorder: Data provided by the French “Temporary Recommendation for Use” 2014-2017 cohort
B. Rolland, Lyon, FRA
14:00-14:30
Closing remarks & Fare well
Hörsaal 3 (Lecture Hall 3)
TOPIC Alcohol and heart disease
10:40-12:00
Session 34: Alcohol-related heart disease
Chairs: P. Rainer; D. Scherr, Graz, AUT
10:40-11:00
Holiday heart: Alcohol-related atrial fibrillation
D. Scherr, Graz, AUT
11:00-11:20
Alcohol-related cardiomyopathy
E. Kolesnik, Graz, AUT
11:20-11:40
Cirrhotic cardiomyopathy (virtual)
S. Möller, Copenhagen, DK
12:00-12:20 COFFEE BREAK AND POSTER VIEWING, Lecture Hall 5
TOPIC Korsakow´s Syndrome update
12:20-13:40
Session 35: Intergrative approach to Korsakoff´s syndrome: an old story revisited
Chair: A. Pitel, Caen, FRA
12:20-12:40
Going downhill? Differences between patients with a “uncomplicated” alcohol use disorder, alcohol-related cognitive impairments, and Korsakoff´s syndrome on cognitive and neuropsychiatric measures
Y. Rensen, Venray, NL
12:40-13:00
Distinct sleep alterations in alcohol use disorder patients with and without Korsakoff`s syndrome
A. Laniepce, Rouen, FRA
13:00-13:20
Thiamine transport and genetics: recent evidences of increased biological vulnerability to alcohol related Wernicke-Korsakoff syndrome
I. Guerrini, London, UK
13:20-13:40
Looking beyond alcohol-related neurocognitive disorders: neuropsychological and brain specificities of Korsakoff’s syndrome compared to Alzheimer’s disease
C. Soussi, Caen, FRA
Hörsaal 4 (Lecture Hall 4)
TOPIC Free oral presentations
10:40-12:00
Session 36: Free oral presentation (2)
Chairs: M. Wojnar, Krakov, POL; E. Palma, London, UK
10:40-10:50
Prenatal alcohol exposure impairs mouse somatosensory cortex development by delaying projection neurons migration
S. Laguesse, Liege, BEL
10:50-11:00
Targeting fibrosis in alcohol-related liver disease: unveiling the therapeutic impact of extracellular matrix remodelling by the cyclophilin inhibitor rencofilstat
U. Rastovic, London, UK
11:00-11:10
Chronic ethanol feeding exacerbates systemic dyslipemia and accelertates aortic lesion formation in LDLR-/- mice on Western diet
C. Hoebinger, Vienna, AUT
11:10-11:20
Chronic pain as a risk factor to suffer alcohol use disorder: Alterations in astrocytes and microglia in the mesocorticolimbic system
P. Andres-Herrera, Valencia, ESP
11:20-11:30
Effects of dietary glycine on metabolic steatohepatitis in diabetic KK-Ay mice through remodeling of hepatic lipid profile
A. Uchiyama, Tokyo, JPN
11:30-11:40
Observational and genetic associations of alcohol with risk of gout
P. K. Im, Oxford, UK
11:40-11:50
Targeting the gut barrier in alcohol-related liver disease: a focus on gut transcriptomics
E. M. Maxan, London, UK
11:50-12:00
Ethanol-induced alterations in the gut-liver axis promotes alcohol-associated liver disease: Protection by betaine treatment
K. Kharbanda, Omaha, USA
12:00-12:20 COFFEE BREAK AND POSTER VIEWING, Lecture Hall 5
TOPIC Intensive care
12:20-13:40
Session 37: Emergencies in alcohol-related disorders
Chairs: L. Kramer, Vienna, AUT; R. Stauber, Graz, AUT
12:20-12:40
Prevention and treatment of acute alcohol withdrawal
D. König-Castillo, Vienna, AUT
12:40-13:00
Hyponatriemia
W. Ribitsch, Graz, AUT
13:00-13:20
The trajectory of acute hepatic decompensation in ALD (virtual)
K. Staufer, Vienna, AUT
13:20-13:40
Management of ACLF in ALD
L. Kramer, Vienna, AUT